Program
UBT251
A development code. Also written as “UBT251 Injection 4.0 mg”, “UBT251 Injection 6.0 mg” and “UBT251 Injection 2.0 mg”.
In Novo Nordisk's own words, UBT251, a triple agonist of the receptors for GLP-1, GIP and glucagon
. Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Sleep Apnea, Obstructive · Fatty Liver, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| The United Laboratories International | 88 open or running | phase 3since Jun 9, 2026 | Aug 13, 2025 | Dec 2026phase 1 · NCT07785934 |
| Novo Nordisk | 44 open or running | phase 2since Feb 1, 2026 | Feb 1, 2026 | Jan 14, 2027phase 2 · NCT07395687 |
- Named in Novo Nordisk’s own pipeline as
UBT251 (GLP-1/GIP/glucagon tri-agonist)
, phase 2, as of Nov 5, 2026 (source).
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseNovo Nordisk licensed it from The United Laboratories, for everywhere outside mainland China, Hong Kong, Macau and Taiwan.Announced Mar 24, 2025 · Source: The United Laboratories and Novo Nordisk (release), Mar 24, 2025
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 13, 2025First studies: 2 phase 2 studiesNew to The United Laboratories InternationalThe United Laboratories International · NCT07145151, NCT07134335
- Feb 1, 2026Novo Nordisk's first study: phase 2 study in OverweightNew to Novo NordiskNovo Nordisk · NCT07395687 · 333 planned · United States, Canada
- Jun 9, 20263 phase 3 studiesPhase 3 reachedThe United Laboratories International · NCT07648225, NCT07653477, NCT07659574
- Jun 19, 2026Phase 2 study in Diabetes Mellitus, Type 2Novo Nordisk · NCT07668388 · 300 planned · United States, Australia, Germany and more
- Jul 13, 20262 phase 1 studiesNovo Nordisk · NCT07710768, NCT07710729
- Aug 11, 2026Phase 3 study in Sleep Apnea, ObstructiveThe United Laboratories International · NCT07767942 · 150 planned
- Aug 13, 2026Phase 1 study in ObesityThe United Laboratories International · NCT07785934 · 48 planned · China
- Sep 1, 2026Phase 3 study in Sleep Apnea, ObstructiveThe United Laboratories International · NCT07806851 · 150 planned
Ahead
- Dec 2026Primary completion: phase 1 study in ObesityThe United Laboratories International · NCT07785934
- Jan 14, 2027Primary completion: phase 2 study in OverweightNovo Nordisk · NCT07395687
- Apr 7, 2027Primary completion: phase 1 study in ObesityNovo Nordisk · NCT07710768
- Apr 27, 2027Primary completion: phase 1 study in OverweightNovo Nordisk · NCT07710729
TargetBeta
“UBT251, a triple agonist of the receptors for GLP-1, GIP and glucagon”company filing, read by Claude · source
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| HRS-4729 | Jiangsu HengRui Medicine | phase 2 | 5 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07806851Sleep Apnea, Obstructive | 3 | Not yet recruiting | The United Laboratories International | Mar 2029 | 150 |
| NCT07785934Obesity · China | 1 | Recruiting | The United Laboratories International | Dec 2026 | 48 |
| NCT07767942Sleep Apnea, Obstructive | 3 | Not yet recruiting | The United Laboratories International | Sep 2028 | 150 |
| NCT07710768Obesity · United States | 1 | Recruiting | Novo Nordisk | Apr 7, 2027 | 44 |
| NCT07710729Overweight · Canada | 1 | Recruiting | Novo Nordisk | Apr 27, 2027 | 40 |
| NCT07668388Diabetes Mellitus, Type 2 · United States, Australia, Germany and more | 2 | Recruiting | Novo Nordisk | Oct 4, 2027 | 300 |
| NCT07659574Diabetes Mellitus, Type 2 · China | 3 | Recruiting | The United Laboratories International | Sep 24, 2027 | 360 |
| NCT07653477Diabetes Mellitus, Type 2 · China | 3 | Recruiting | The United Laboratories International | Feb 29, 2028 | 956 |
| NCT07648225Obesity · China | 3 | Active, not recruiting | The United Laboratories International | Sep 29, 2027 | 600 |
| NCT07395687Overweight · United States, Canada | 2 | Recruiting | Novo Nordisk | Jan 14, 2027 | 333 |
| NCT07145151Metabolic Dysfunction-associated Steatohepatitis (MASH) · China | 2 | Recruiting | The United Laboratories International | Jun 4, 2027 | 156 |
| NCT07134335Obesity · China | 2 | Recruiting | The United Laboratories International | Jul 11, 2030 | 180 |
How it is read
Names in the registry
- “UBT251”, 13 entries
- “UBT251 Injection 4.0 mg”, 2 entries
- “UBT251 Injection 6.0 mg”, 2 entries
- “UBT251 Injection 2.0 mg”, 1 entry
- “UBT251 Injection 2.0 mg group”, 1 entry
Codes read as this program: UBT251.
Conditions, from the studies’ own filings
- Obesity, 6 studies
- Diabetes Mellitus, Type 2, 3 studies
- Sleep Apnea, Obstructive, 2 studies
- Fatty Liver, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.